Article
A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Cancer treatment and research communications - 1 Jan 2021
Kartolo Adi, Feilotter Harriet, Hopman Wilma, Fung Andrea S, Robinson Andrew
Abstract excerpt
AIM: This study aimed to evaluate the impact of KRAS status on the efficacy of first-line immune checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with advanced incurable or metastatic NSCLC with PD-L1 ≥50% treated with palliative-intent, single-agent PD-1/PD-L1 inhibitors at the Cancer Centre of Southeastern Ontario were included. KRAS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.